{"favorite_id": 10142, "calc_type": "calculator", "dosing": false, "full_title_en": "Tokyo Guidelines for Acute Cholangitis 2018", "short_title_en": "Tokyo Guidelines 2018 (Acute Cholangitis)", "medium_description_en": "<span id=\"docs-internal-guid-26e43dfa-7fff-9bf1-7415-52f2f4915433\">Provides diagnostic criteria and severity grading for acute cholangitis.</span>", "short_description_en": "Acute cholangitis diagnosis and grading.", "before_use": "", "instructions_en": "", "purpose_en": ["Diagnosis"], "disease_en": ["Cholangitis"], "specialty_en": ["Surgery (General)", "Internal Medicine", "Hepatology", "Hospitalist Medicine", "Gastroenterology", "Critical Care"], "chief_complaint_en": ["Fever", "Jaundice", "Abdominal Pain", "Vomiting"], "system_en": ["Hepatic", "Gastrointestinal"], "search_abbreviation_en": ["Acute cholangitis", "ascending cholangitis", "tokyo guidelines", "cholangitis", "tokyo guidelines 2018"], "slug": "tokyo-guidelines-acute-cholangitis-2018", "seo": {"meta_description_en": "The Tokyo Guidelines for Acute Cholangitis 2018 provides diagnostic criteria and severity grading for acute cholangitis.", "keywords_en": "Acute cholangitis, tokyo guidelines, ascending cholangitis, cholangitis, tokyo guidelines 2018"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-659ce8cb-7fff-2d77-e098-26f4bf313cf6\">Use in patients with suspected acute cholangitis (i.e., fever, jaundice, right upper quadrant pain, altered mental status, and/or hemodynamic instability).</p>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-866f0a6a-7fff-49e4-b8d3-3dae923102f1\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">More extensively studied in non-US populations.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Conditions such as acute hepatitis and acute cholecystitis may have some similarities in presentation and should be ruled out.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Although MRI and <abbr title=\"Magnetic resonance cholangiopancreatography\">MRCP</abbr> have the highest sensitivity/specificity for bile duct dilation, abdominal US followed by CT abdomen are more readily available and cost-effective, and thus should be performed initially.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Procalcitonin is useful in assessing the severity of cholangitis, <em>not</em> in the diagnosis.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">For patients with grade II-III (moderate to severe) cholangitis, transfer to a hospital that can perform biliary drainage and provide ICU level care is recommended.</p>\n</li>\n</ul>", "why_use_en": "<p></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Objectively guides diagnosis and management of patients with acute cholangitis in terms of timing and need for biliary drainage and supportive care.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Charcot&rsquo;s triad (fever, right upper quadrant pain, jaundice) has high specificity but low sensitivity for&nbsp;acute cholangitis&nbsp;(<a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.512\" target=\"_blank\">Kiriyama et al 2017</a>).</p>\n</li>\n</ul>"}, "next_steps": {"advice_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">If a definitive diagnosis cannot be made on presentation, it is reasonable to reassess the patient using the diagnostic criteria every 6-12 hrs.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In patients with grade I (mild) disease, if no response to the initial treatment is observed within 24 hr, perform biliary drainage immediately.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In patients with grade II (moderate) or grade III (severe) disease, perform biliary drainage as soon as possible along with supportive care and antibiotics. Also, obtain blood cultures and bile cultures in such patients.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Consider treating the etiology of acute cholangitis with endoscopic (endoscopic sphincterotomy or choledocholithotomy), percutaneous, or operative intervention once the acute illness has resolved. Cholecystectomy should be performed for gallstones after the acute cholangitis has resolved.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Antibiotics should be chosen based on severity of disease, location of infection (community or hospital acquired), and local susceptibilities (see <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29090866\" target=\"_blank\">Tokyo Guidelines 2018 Antimicrobial Therapy for Acute Cholangitis and Cholecystitis</a>).</p>\n</li>\n</ul>", "management_en": "<p><span id=\"docs-internal-guid-fcb6e89d-7fff-4f31-9498-cd61012daae7\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Upon diagnosis of acute cholangitis (regardless of severity) initial treatment generally consists of antibiotics, fluid resuscitation, electrolyte repletion, and appropriate analgesic administration.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Grade I (mild):</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In most cases, initial treatment as above is sufficient, and most patients do not require biliary drainage.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">However, biliary drainage should be considered if a patient does not respond to initial treatment within 24 hrs.</p>\n</li>\n</ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Grade II (moderate):</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early (within 48 hrs of admission) endoscopic or percutaneous transhepatic biliary drainage is indicated.</p>\n</li>\n</ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Grade III (severe):</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Treat underlying sepsis aggressively with respiratory (tracheal intubation) and circulatory (pressors) support.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emergent (as soon as patient is hemodynamically stable) endoscopic or percutaneous transhepatic biliary drainage is indicated.</p>\n</li>\n</ul>\n</ul>", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\"></p>\n<p dir=\"ltr\">Patient must have a suspected diagnosis (&ge;1 item in A + &ge;1 item in B or C) or definite diagnosis (&ge;1 item in A, B, and C) to meet entry criteria for severity grading, see table below:</p>\n<p dir=\"ltr\"></p>\n<div dir=\"ltr\">\n<p><strong>Diagnosis:</strong></p>\n<table><colgroup><col width=\"67\" /><col width=\"382\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Part A</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Systemic inflammation</p>\n</td>\n<td>\n<p dir=\"ltr\">Fever (&gt;38&deg;C/100.4&deg;F) and/or shaking chills</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Laboratory data: evidence of inflammatory response (WBC &lt;4 or &gt;10 x1,000/&mu;L and/or CRP &ge;1 mg/dL)</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Part B</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Cholestasis</p>\n</td>\n<td>\n<p dir=\"ltr\">Jaundice (total bilirubin &ge;2 mg/dL)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Laboratory data: abnormal liver enzymes (ALP, &gamma;GTP, AST, ALT levels &gt;1.5 x STD)</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Part C</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Imaging</p>\n</td>\n<td>\n<p dir=\"ltr\">Biliary dilatation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Evidence of the etiology on imaging (stricture, stone, stent, etc.)&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\"></p>\n<p dir=\"ltr\"><strong>Severity grading:</strong></p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"449\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade III&nbsp;(dysfunction in&nbsp;&ge;1&nbsp;of the following):</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Cardiovascular dysfunction: hypotension requiring dopamine &ge;5 &mu;g/kg per min or any dose of norepinephrine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Neurological dysfunction: disturbance of consciousness</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\" style=\"text-align: left;\">Respiratory dysfunction: PaO\u2082/FiO\u2082 ratio &lt;300</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Renal dysfunction: oliguria or creatinine &gt;2.0 mg/dL</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hepatic dysfunction: <abbr title=\"Prothrombin time - International normalized ratio\">PT\u2010INR</abbr> &gt;1.5</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hematological dysfunction: platelet count &lt;100,000/mm<font size=\"1\">&sup3;</font></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade II&nbsp;(&ge;2 of the following conditions):</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Abnormal WBC count (&gt;12,000/mm&sup3;<sup>&nbsp;</sup>or &lt;4,000/mm&sup3;)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">High fever (&ge;39&deg;C/102.2&deg;F)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Age &ge;75 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hyperbilirubinemia (total bilirubin &ge;5 mg/dL)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hypoalbuminemia (&lt;0.7 x upper limit of normal)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade I</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Does not meet the criteria of Grade III or Grade II acute cholangitis at initial diagnosis</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"57\" /><col width=\"107\" /><col width=\"285\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Grade</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Acute cholangitis severity</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Recommendations</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">I</p>\n</td>\n<td>\n<p dir=\"ltr\">Mild</p>\n</td>\n<td>\n<p dir=\"ltr\">Antibiotics and general supportive care; consider biliary drainage if no response to initial treatment</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">II</p>\n</td>\n<td>\n<p dir=\"ltr\">Moderate</p>\n</td>\n<td>\n<p dir=\"ltr\">Antibiotics and general supportive care; early endoscopic or percutaneous transhepatic biliary drainage is indicated</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">III</p>\n</td>\n<td>\n<p dir=\"ltr\">Severe</p>\n</td>\n<td>\n<p dir=\"ltr\">Initial treatment with antibiotics, urgent biliary drainage, appropriate respiratory/circulatory management</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><span id=\"docs-internal-guid-eb5f11d4-7fff-87b7-5303-b10bce5a997f\"></span><span id=\"docs-internal-guid-eb5f11d4-7fff-87b7-5303-b10bce5a997f\"><br /></span></p>", "evidence_based_medicine_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The <a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.509\" target=\"_blank\">Tokyo Guidelines 2018 (TG18)</a> are a revision of the <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23307001\" target=\"_blank\">2013 guidelines (TG13)</a>, and incorporate new evidence based on validation studies of TG13.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><a href=\"https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.458\" target=\"_blank\">Kiriyama et al (2017)</a> studied 6,063 patients who were clinically diagnosed with&nbsp;acute cholangitis, and found that the TG13 guidelines diagnosed 90% of these patients retrospectively with&nbsp;acute cholangitis. 30-day mortality rates of patients with Grade III, Grade II, and Grade I were 5.1%, 2.6%, and 1.2%, respectively, and increased significantly along with disease severity.</p>\n</li>\n</ul>", "references_list": {"Original/Primary Reference": [{"href": "https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.512", "text": "Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):17-30."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/23307001", "text": "Kiriyama S, Takada T, Strasberg SM, et al. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2013;20(1):24-34."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/29090866", "text": "Gomi H, Solomkin JS, Schlossberg D, et al. Toyko Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2017."}, {"href": "https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.458", "text": "Kiriyama S, Takada T, Hwang TL, et al. Clinical application and verification of the TG13 diagnostic and severity grading criteria for acute cholangitis: an international multicenter observational study. J Hepatobiliary Pancreat Sci. 2017;24(6):329-337."}, {"href": "https://onlinelibrary.wiley.com/doi/full/10.1002/jhbp.509", "text": "Miura F, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018;25(1):31-40."}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "<p>Joseph Mizrahi, MD, is an internal medicine resident at Stony Brook University Hospital in New York. Born and raised in Brooklyn, New York, Dr. Mizrahi received his medical degree from the Sackler School of Medicine at Tel Aviv University, and he is also currently a student at the School of Public Health at Stony Brook University. Dr. Mizrahi's areas of interest include gastroenterology and colorectal cancer prevention and screening.</p>", "firstName": "Joseph", "img": "https://cdn-web-img.mdcalc.com/people/joseph-mizrahi.jpg", "lastName": "Mizrahi", "name": "Joseph Mizrahi, MD", "target": "joseph-mizrahi", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": [{"name": "Lionel D'Souza, MBBS"}]}, "creator": [{"name": "Dr. Fumihiko Miura", "creator_info": {"about_en": "Fumihiko Miura, MD, is a physician in the department of surgery at the Teikyo University School of Medicine in Tokyo, Japan. Dr. Miura's primary research is focused on the grading and management of acute cholangitis.", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Miura%20F%5BAuthor%5D&cauthor=true&cauthor_uid=28941329"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "subheading", "subheading": "Part A: Systemic Inflammation", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Fever and/or shaking chills", "name": "fever", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": ">38\u00b0C/100.4\u00b0F", "optional": false}, {"type": "toggle", "label_en": "Laboratory data: evidence of inflammatory response", "name": "lab", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "WBC <4 or >10 x1,000/\u03bcL and/or CRP \u22651 mg/dL", "optional": false}, {"type": "subheading", "subheading": "Part B: Cholestasis", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Jaundice", "name": "jaundice", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "Total bilirubin \u22652 mg/dL", "optional": false}, {"type": "toggle", "label_en": "Laboratory data: abnormal liver enzymes", "name": "lab2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "ALP, \u03b3GTP, AST, ALT levels >1.5 x STD", "optional": false}, {"type": "subheading", "subheading": "Part C: Imaging", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Biliary dilatation", "name": "bili", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Evidence of the etiology on imaging", "name": "evidence", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "tips_en": "Stricture, stone, stent, etc.", "optional": false}, {"type": "subheading", "subheading": "Grading", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Cardiovascular dysfunction", "name": "cardio", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "Hypotension requiring dopamine \u22655 \u03bcg/kg per min or any dose of norepinephrine", "optional": false}, {"type": "toggle", "label_en": "Neurological dysfunction", "name": "neuro", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "Disturbance of consciousness", "optional": false}, {"type": "toggle", "label_en": "Respiratory dysfunction", "name": "resp", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "PaO\u2082/FiO\u2082 ratio <300", "optional": false}, {"type": "toggle", "label_en": "Renal dysfunction", "name": "renal", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "Oliguria or creatinine >2.0 mg/dL", "optional": false}, {"type": "toggle", "label_en": "Hepatic dysfunction", "name": "hepatic", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "<abbr title=\"Prothrombin time - International normalized ratio\">PT\u2010INR</abbr> >1.5", "optional": false}, {"type": "toggle", "label_en": "Hematological dysfunction", "name": "hema", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "Platelet count <100,000/mm\u00b3", "optional": false}, {"type": "toggle", "label_en": "Abnormal WBC count", "name": "wbc", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": ">12,000/mm\u00b3 or <4,000/mm\u00b3", "optional": false}, {"type": "toggle", "label_en": "High fever", "name": "fever2", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "\u226539\u00b0C/102.2\u00b0F", "optional": false}, {"type": "toggle", "label_en": "Age \u226575 years", "name": "age", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Hyperbilirubinemia", "name": "hyper", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "Total bilirubin \u22655 mg/dL", "optional": false}, {"type": "toggle", "label_en": "Hypoalbuminemia", "name": "hypo", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "(fever + lab) > 0 && (jaundice + lab2 + bili + evidence) > 0", "show_points": false, "default": 0, "tips_en": "<0.7 x upper limit of normal", "optional": false}], "md5": "4ee498c1f78d97c492841072fab5b6b9", "cmeVersion": "10142.1", "related_calcs": [{"calcId": 10240, "short_title_en": "CLIF-C ACLF", "slug": "clif-c-aclf-acute-chronic-liver-failure"}, {"calcId": 10389, "short_title_en": "IRAE for GI Toxicity - Hepatitis", "slug": "immune-related-adverse-events-gi-toxicity-hepatitis"}, {"calcId": 3984, "short_title_en": "AIR Score", "slug": "appendicitis-inflammatory-response-air-score"}]}